SCHEMBL852125

SCHEMBL852125

Oc1ccc(-c2ccoc2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 7/20 0.46
CYP11B1 P15538 2/20 0.46
CYP11B2 P19099 2/20 0.46
PIM1 P11309 1/20 0.40
PPARA Q07869 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
PELI1 Q96FA3 1/20 0.36
KDM1A O60341 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL764319 0.77 CYP11B1 (0.56) FYNCYP11B1CYP11B2PIM1PPARA
SCHEMBL28657158 0.76 NT5E (0.45) FYNPPARAMAPTMEN1USP2
SCHEMBL15646952 0.74 PELI1 (0.45) FYNCYP11B1CYP11B2PIM1MAPT
SCHEMBL2717909 0.74 CYP11B1 (0.47) FYNCYP11B1CYP11B2PIM1ALDH1A1
SCHEMBL30958843 0.73 CCR1 (0.46) MAPTHSD17B1HSD17B2MEN1USP2
SCHEMBL1070654 0.73 CCR1 (0.46) MAPTHSD17B1HSD17B2MEN1USP2
SCHEMBL12463850 0.73 FYN (0.46) FYNPIM1MEN1USP2ALDH1A1
SCHEMBL2716516 0.73 CYP11B1 (0.59) FYNCYP11B1CYP11B2PIM1MAPT
SCHEMBL30567008 0.73 CYP11B1 (0.49) FYNCYP11B1CYP11B2PIM1PPARA
SCHEMBL2716514 0.73 CYP11B1 (0.49) FYNCYP11B1CYP11B2PIM1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
CN-102459202-A Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS INC 2012-05-16 CN disclosed
EP-2432771-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
WO-2010135360-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 FYN 2138/4885CYP11B1 605/4885CYP11B2 721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.